Rufinamide Tablet, Film Coated
NDC Package 51148-009-01
Package Information
Rufinamide tablets is rufinamide is used with other medications to prevent or control seizures (epilepsy) associated with Lennox-Gastaut syndrome (LGS). This formulation utilizes a tablet, film coated delivery system. Marketed by Bushu Pharmaceuticals, Ltd., this product is identified by NDC 51148-009.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51148 - Bushu Pharmaceuticals, Ltd.
- 51148-009 -
- 51148-009-01 - 1 BAG in 1 DRUM / 40000 TABLET, FILM COATED in 1 BAG
- 51148-009 -
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51148-009-01 identifies a specific commercial package of 1 bag in 1 drum / 40000 tablet, film coated in 1 bag of Rufinamide (UNFINISHED drug), drug for further processing labeled by Bushu Pharmaceuticals, Ltd.. This tablet, film coated is formulated for use and contains rufinamide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bushu Pharmaceuticals, Ltd. on November 14, 2008. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Rufinamide is used with other medications to prevent or control seizures (epilepsy) associated with Lennox-Gastaut syndrome (LGS). This medication is an anticonvulsant. Rufinamide is thought to work by acting on the sodium channels in the brain that carry excessive electrical charges that may cause seizures.
How is this Bushu Pharmaceuticals, Ltd. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51148000901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.